NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyPreclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
About This Grant
This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.
Grant Summary
Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) is a National Institutes of Health grant providing funding that varies by award for municipality, small business, school district. Applications are due 2027-07-02 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 1,200+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
How to Apply
Not stated by funder
2027-07-02
- 1Confirm your organization is eligible for Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed): Frequently Asked Questions
Who is eligible for the Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)?
Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) is offered by National Institutes of Health. The listing names these applicant types: municipality, small business, school district, tribal government, nonprofit, university. It is open to organizations nationwide unless the funder specifies otherwise. The funder's eligibility section is the authority, so confirm your organization type, location, and the population or project served against it before applying.
How much funding does the Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) provide?
National Institutes of Health does not publish a set award amount for Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed), so award sizes vary. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs, and confirm the expected range with the funder.
When is the Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) deadline?
Applications for Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) are due 2027-07-02 (open). Because deadlines can change, verify the date with the funder, National Institutes of Health, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)?
To apply for Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.
Browse More Grants
Related Grants
State Veterans Home Construction Grant Program
Construction of State Home Facilities — up to $275M
Advancing Global Health
Bureau of Global Health Security and Diplomacy — up to $250M
Title X Family Planning Services Grants
Office of the Assistant Secretary for Health — up to $22M
Fiscal Year (FY) 2027 Service Area Competition (SAC)
Health Resources and Services Administration — up to $10.1M
Occupational Safety and Health Education and Research Centers (T42)
Centers for Disease Control and Prevention - ERA — up to $9M
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
National Institutes of Health — up to $8M